Skip to main navigation Skip to search Skip to main content

Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: Progress and emerging issues in research and policy

  • University of California la Jolla
  • University of California
  • University of California Los Angeles
  • World Health Organization
  • Johns Hopkins Bloomberg School of Public Health

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Abstract

Background: In this article, we present recent evidence from studies focused on the implementation, effectiveness and costeffectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. Discussion: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive "combination prevention" programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. Conclusions: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers' openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.

Original languageEnglish
Article number21108
JournalJournal of the International AIDS Society
Volume19
DOIs
StatePublished - 18 Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality
  3. SDG 16 - Peace, Justice and Strong Institutions
    SDG 16 Peace, Justice and Strong Institutions
  4. SDG 17 - Partnerships for the Goals
    SDG 17 Partnerships for the Goals

Keywords

  • Acceptability
  • Combination prevention
  • HIV
  • Health systems
  • Implementation science
  • Pre-exposure prophylaxis
  • Program cost
  • Scale-up

Fingerprint

Dive into the research topics of 'Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: Progress and emerging issues in research and policy'. Together they form a unique fingerprint.

Cite this